Red Teaming in Hyderabad · Pharma & US-Healthcare GCC

Hyderabad red-teaming has a sharply defined buyer profile no other Indian metro matches. Top-5 generics with Shameerpet R&D campuses, Patancheru API plants and Bachupally formulation belts run annual adversary-simulation engagements to evidence that motivated threat actors cannot corrupt clinical-trial data integrity, exfiltrate IP, or compromise GMP-validated systems ahead of the next FDA / EMA / DCGI inspection. Clinical-trial SaaS operators in Genome Valley run red-team engagements to satisfy sponsor (US pharma giant) cyber-resilience expectations. US-healthcare GCCs in Gachibowli and Q City run red-team engagements aligned to the US parent's HIPAA / HITRUST adversary-simulation cadence. Macksofy's Hyderabad red-team bench is engineered for these three sub-segments with separate emulation profiles.

Pharma threat-actor emulation is the headline capability. Real adversaries active in the pharma sector — APT41 (intellectual-property exfiltration), Lazarus / DarkSide (financial-motivation against pharma), MuddyWater (regional state-adjacent against critical infrastructure), and FIN-style actors targeting reimbursement / payer-data flows — are emulated per the customer's threat model. The objective is calibrated to the customer's specific risk. For a Top-5 generics with US-bound clinical-trial data, the objective is typically 'exfiltrate the eCRF / EDC clinical-trial-data pre-FDA-PAI without QA detection by D+15'. For a CRO, the objective is typically 'corrupt the eTMF audit-trail integrity without sponsor or regulator detection'. The plan is signed by the CTO, the CISO and the QA director before the operations team is informed (or, in a blind engagement, kept blind).

Initial-access vectors in pharma red-team engagements run lanes that other industries do not. Vendor-portal compromise against the CDS / LIMS / eTMF vendor support portal (high-yield because the vendor portal is often less hardened than the customer environment, and the vendor's access to the customer environment is privileged). Spear-phish against the QA director's office and the regulatory-affairs function (the lure calibrated to FDA / EMA / DCGI inspection cycle news). Physical access via tailgating a Genome Valley R&D campus lobby or QC lab cafeteria. Public-facing exploit chains against the customer's regulatory-affairs submission portal or sponsor-collaboration platform.

Post-exploitation in pharma red-team engagements traverses ALL three estate types — corporate IT, R&D network, and QC lab network. The R&D network is the highest-value target (clinical-trial data, IP, sponsor-side data) but also the most regulated (validation-state preservation, ALCOA+ contemporaneity). The QC lab network houses lab-instrument workstations integrated into LIMS / CDS — these are valid lateral-movement footholds and the engagement's controlled-stop is at the data-integrity boundary (no actual tampering, evidence via screenshot + hash). The corporate IT network is the access lane to both R&D and QC lab segments and where the AD privilege paths typically run.

Clinical-trial SaaS red-team engagements have a different shape. The customer-facing platform (sponsor-side or CRO-side) is the target surface. Multi-tenant sponsor-isolation, eTMF audit-trail integrity, EDC clinical-trial-data exfiltration, and (where applicable) the AI-investigator-assistant LLM surface. Adversary emulation is typically calibrated to sponsor-cyber-resilience expectations — most US pharma sponsors require their clinical-trial SaaS vendors to run an annual red-team with sponsor-data-exfil objectives. The deliverable doubles as the sponsor's annual cyber-resilience attestation.

US-healthcare GCC red-team engagements align to US-parent adversary-simulation cadence — typically HITRUST CSF-aligned, parent-specific (Optum, UnitedHealth, Cigna, CVS Health each have their own internal red-team standards), and reported in the format the parent's compliance function expects. The engagement closes the parent's annual HIPAA penetration-test attestation and the HITRUST CSF e-3 control evidence. Onsite legs at Gachibowli or Q City include a virtual closing call with the US parent's regional CISO and (where applicable) the parent's adversary-emulation lead.

Procurement reality matters. Pharma red-team engagements close through the CTO, the CISO and the QA director, often with the head of regulatory-affairs copied because of inspection-cycle alignment. Engagement letters include trespass-and-deception waivers, QA-witness scheduling for any lab-instrument scope, controlled-stop at the data-integrity boundary acknowledgement, and the no-state-alteration acknowledgement standard for GMP-validated systems. Clinical-trial SaaS engagements close through the CTO and head of customer security with the sponsor-side compliance function copied for sponsor-data-exfil objectives. US-healthcare GCC engagements close through the Indian CISO with the US parent's regional CISO and parent's adversary-emulation lead copied.

Onsite cadence — HITEC City regional hub means two-hour onsite SLA across Madhapur, Gachibowli, Banjara Hills, Kondapur and Genome Valley. Patancheru / Bachupally / Shameerpet are 60-90 minutes from the hub. Pharma red-team engagements typically run 6-8 weeks — 1 week threat-model and recon, 4-5 weeks active operations across all three estate types, 1-2 weeks reporting and inspection-defence rehearsal. Clinical-trial SaaS and US-healthcare GCC engagements run 5-6 weeks. All engagements include a paired detection-engineering analyst with the customer's blue-team for the closing week.